Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T59631
(Former ID: TTDNC00489)
|
|||||
Target Name |
Programmed cell death protein 1 (PD-1)
|
|||||
Synonyms |
hPD1; hPD-1; Protein PD1; Protein PD-1; PD1; CD279
Click to Show/Hide
|
|||||
Gene Name |
PDCD1
|
|||||
Target Type |
Successful target
|
[1] | ||||
Disease | [+] 8 Target-related Diseases | + | ||||
1 | Demodex blepharitis ICD-11: 1G07 | |||||
2 | Endometrial cancer [ICD-11: 2C76] | |||||
3 | Hodgkin lymphoma [ICD-11: 2B30] | |||||
4 | Lung cancer [ICD-11: 2C25] | |||||
5 | Melanoma [ICD-11: 2C30] | |||||
6 | Nasopharyngeal cancer ICD-11: 2B6B | |||||
7 | Stomach cancer [ICD-11: 2B72] | |||||
8 | Ureteral cancer [ICD-11: 2C92] | |||||
Function |
Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2. Following T-cell receptor (TCR) engagement, PDCD1 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation. Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta. Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self.
Click to Show/Hide
|
|||||
BioChemical Class |
Immunoglobulin
|
|||||
UniProt ID | ||||||
Sequence |
MQIPQAPWPVVWAVLQLGWRPGWFLDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTS
ESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGT YLCGAISLAPKAQIKESLRAELRVTERRAEVPTAHPSPSPRPAGQFQTLVVGVVGGLLGS LVLLVWVLAVICSRAARGTIGARRTGQPLKEDPSAVPVFSVDYGELDFQWREKTPEPPVP CVPEQTEYATIVFPSGMGTSSPARRGSADGPRSAQPLRPEDGHCSWPL Click to Show/Hide
|
|||||
3D Structure | Click to Show 3D Structure of This Target | AlphaFold |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Approved Drug(s) | [+] 9 Approved Drugs | + | ||||
1 | Cemiplimab | Drug Info | Approved | Cutaneous squamous cell carcinoma | [2] | |
2 | Dostarlimab | Drug Info | Approved | Endometrial cancer | [3] | |
3 | MK-3475 | Drug Info | Approved | Melanoma | [1], [4] | |
4 | Nivolumab | Drug Info | Approved | Melanoma | [5], [6] | |
5 | Pembrolizumab | Drug Info | Approved | Melanoma | [7], [8] | |
6 | Retifanlimab | Drug Info | Approved | Neuroendocrine cancer | [9] | |
7 | Sintilimab | Drug Info | Approved | Hodgkin lymphoma | [10] | |
8 | Tislelizumab | Drug Info | Approved | Hodgkin lymphoma | [11] | |
9 | Toripalimab | Drug Info | Approved in China | Melanoma | [12] | |
Clinical Trial Drug(s) | [+] 49 Clinical Trial Drugs | + | ||||
1 | AK04 | Drug Info | Phase 3 | Actinic keratosis | [13] | |
2 | Balstilimab | Drug Info | Phase 3 | Cervical cancer | [14] | |
3 | BGB-A317 | Drug Info | Phase 3 | Hepatocellular carcinoma | [15] | |
4 | CS-1003 | Drug Info | Phase 3 | Hepatocellular carcinoma | [16] | |
5 | IBI-308 | Drug Info | Phase 3 | Bronchioalveolar carcinoma | [8] | |
6 | INCSHR1210 | Drug Info | Phase 3 | Bronchioalveolar carcinoma | [8] | |
7 | Nofazinlimab | Drug Info | Phase 3 | Liver cancer | [16] | |
8 | PDR001 | Drug Info | Phase 3 | Melanoma | [17] | |
9 | Sasanlimab | Drug Info | Phase 3 | Non-muscle invasive bladder cancer | [18] | |
10 | Spartalizumab | Drug Info | Phase 3 | Melanoma | [8] | |
11 | AGEN2034 | Drug Info | Phase 2 | Solid tumour/cancer | [15], [19] | |
12 | AK104 | Drug Info | Phase 2 | Cervical cancer | [20] | |
13 | AZD7789 | Drug Info | Phase 2 | Hodgkin lymphoma | [21] | |
14 | JNJ 63723283 | Drug Info | Phase 2 | Ulcerative colitis | [8] | |
15 | JTX-4014 | Drug Info | Phase 2 | Non-small-cell lung cancer | [22] | |
16 | Lorigerlimab | Drug Info | Phase 2 | Prostate cancer | [23] | |
17 | M7824 | Drug Info | Phase 2 | Solid tumour/cancer | [15], [19] | |
18 | Peresolimab | Drug Info | Phase 2 | Rheumatoid arthritis | [24] | |
19 | RO7121661 | Drug Info | Phase 2 | Esophageal squamous cell carcinoma | [25] | |
20 | SAR445877 | Drug Info | Phase 2 | Aggressive cancer | [26] | |
21 | Vudalimab | Drug Info | Phase 2 | Prostate cancer | [27] | |
22 | Cetrelimab | Drug Info | Phase 1/2 | Solid tumour/cancer | [28] | |
23 | MGD013 | Drug Info | Phase 1/2 | Hepatocellular carcinoma | [29] | |
24 | Rilvegostomig | Drug Info | Phase 1/2 | Non-small-cell lung cancer | [30] | |
25 | 609A | Drug Info | Phase 1 | Solid tumour/cancer | [31] | |
26 | ADPT01 | Drug Info | Phase 1 | Breast cancer | [32] | |
27 | AMG 404 | Drug Info | Phase 1 | Solid tumour/cancer | [33] | |
28 | AMP-224 | Drug Info | Phase 1 | Solid tumour/cancer | [34] | |
29 | APL-501 | Drug Info | Phase 1 | Solid tumour/cancer | [35] | |
30 | BI 754091 | Drug Info | Phase 1 | Neoplasm | [36] | |
31 | BI-754091 | Drug Info | Phase 1 | Solid tumour/cancer | [8] | |
32 | CBT-501 | Drug Info | Phase 1 | Solid tumour/cancer | [15] | |
33 | CC-90006 | Drug Info | Phase 1 | Psoriasis vulgaris | [37] | |
34 | CDX-527 | Drug Info | Phase 1 | Solid tumour/cancer | [38] | |
35 | GSK2661380 | Drug Info | Phase 1 | Solid tumour/cancer | [34] | |
36 | IBI318 | Drug Info | Phase 1 | Non-small-cell lung cancer | [39] | |
37 | LZM009 | Drug Info | Phase 1 | Solid tumour/cancer | [8] | |
38 | MEDI0680 | Drug Info | Phase 1 | Solid tumour/cancer | [40] | |
39 | MEDI5752 | Drug Info | Phase 1 | Solid tumour/cancer | [41] | |
40 | MGD019 | Drug Info | Phase 1 | Solid tumour/cancer | [42] | |
41 | PF-06801591 | Drug Info | Phase 1 | Solid tumour/cancer | [8] | |
42 | RG6139 | Drug Info | Phase 1 | Solid tumour/cancer | [43] | |
43 | RG6279 | Drug Info | Phase 1 | Solid tumour/cancer | [44] | |
44 | SI-B003 | Drug Info | Phase 1 | Solid tumour/cancer | [45] | |
45 | Sym021 | Drug Info | Phase 1 | Solid tumour/cancer | [8] | |
46 | SYN125 | Drug Info | Phase 1 | Solid tumour/cancer | [46] | |
47 | TSR-042 | Drug Info | Phase 1 | Solid tumour/cancer | [8] | |
48 | XmAb20717 | Drug Info | Phase 1 | Solid tumour/cancer | [8] | |
49 | XmAb23104 | Drug Info | Phase 1 | Solid tumour/cancer | [47] | |
Patented Agent(s) | [+] 9 Patented Agents | + | ||||
1 | 1,2,4-oxadiazole derivative 1 | Drug Info | Patented | Solid tumour/cancer | [48] | |
2 | 1,2,4-oxadiazole derivative 2 | Drug Info | Patented | Solid tumour/cancer | [48] | |
3 | 1,3,4-oxadiazole derivative 1 | Drug Info | Patented | Solid tumour/cancer | [48] | |
4 | 1,3,4-oxadiazole derivative 2 | Drug Info | Patented | Solid tumour/cancer | [48] | |
5 | Cyclic compound 1 | Drug Info | Patented | Solid tumour/cancer | [48] | |
6 | Cyclic compound 2 | Drug Info | Patented | Solid tumour/cancer | [48] | |
7 | Cyclic compound 3 | Drug Info | Patented | Solid tumour/cancer | [48] | |
8 | PMID30107136-Compound-Example15 | Drug Info | Patented | Solid tumour/cancer | [48] | |
9 | PMID30107136-Compound-Example16 | Drug Info | Patented | Solid tumour/cancer | [48] | |
Mode of Action | [+] 4 Modes of Action | + | ||||
Modulator | [+] 4 Modulator drugs | + | ||||
1 | Cemiplimab | Drug Info | [2] | |||
2 | Nivolumab | Drug Info | [1] | |||
3 | AMP-224 | Drug Info | [66] | |||
4 | CBT-501 | Drug Info | [19] | |||
Inhibitor | [+] 39 Inhibitor drugs | + | ||||
1 | Dostarlimab | Drug Info | [49] | |||
2 | Retifanlimab | Drug Info | [8], [19] | |||
3 | Sintilimab | Drug Info | [10] | |||
4 | Toripalimab | Drug Info | [50] | |||
5 | BGB-A317 | Drug Info | [19] | |||
6 | INCSHR1210 | Drug Info | [19] | |||
7 | AGEN2034 | Drug Info | [15], [19] | |||
8 | AK104 | Drug Info | [56] | |||
9 | JTX-4014 | Drug Info | [58] | |||
10 | RO7121661 | Drug Info | [61] | |||
11 | 609A | Drug Info | [65] | |||
12 | ADPT01 | Drug Info | [32] | |||
13 | AMG 404 | Drug Info | [33] | |||
14 | APL-501 | Drug Info | [67] | |||
15 | BI 754091 | Drug Info | [68] | |||
16 | CDX-527 | Drug Info | [69] | |||
17 | GSK2661380 | Drug Info | [70] | |||
18 | IBI318 | Drug Info | [71] | |||
19 | MEDI5752 | Drug Info | [72] | |||
20 | MGD019 | Drug Info | [73] | |||
21 | RG6139 | Drug Info | [74] | |||
22 | 1,2,4-oxadiazole derivative 1 | Drug Info | [48] | |||
23 | 1,2,4-oxadiazole derivative 2 | Drug Info | [48] | |||
24 | 1,3,4-oxadiazole derivative 1 | Drug Info | [48] | |||
25 | 1,3,4-oxadiazole derivative 2 | Drug Info | [48] | |||
26 | Cyclic compound 1 | Drug Info | [48] | |||
27 | Cyclic compound 2 | Drug Info | [48] | |||
28 | Cyclic compound 3 | Drug Info | [48] | |||
29 | PMID30107136-Compound-Example15 | Drug Info | [48] | |||
30 | PMID30107136-Compound-Example16 | Drug Info | [48] | |||
31 | AUNP-12 | Drug Info | [8] | |||
32 | PMID30247903-Compound-General structure16 | Drug Info | [8] | |||
33 | PMID30247903-Compound-General structure17 | Drug Info | [8] | |||
34 | PMID30247903-Compound-General structure20 | Drug Info | [8] | |||
35 | PMID30247903-Compound-General structure21 | Drug Info | [8] | |||
36 | PMID30247903-Compound-General structure22 | Drug Info | [8] | |||
37 | PMID30247903-Compound-General structure23 | Drug Info | [8] | |||
38 | PMID30247903-Compound-General structure24 | Drug Info | [8] | |||
39 | PMID30247903-Compound-General structure25 | Drug Info | [8] | |||
Antagonist | [+] 2 Antagonist drugs | + | ||||
1 | PDR001 | Drug Info | [37] | |||
2 | CC-90006 | Drug Info | [37] | |||
antagonist | [+] 3 antagonist drugs | + | ||||
1 | PMID30247903-Compound-General structure13 | Drug Info | [8] | |||
2 | PMID30247903-Compound-General structure14 | Drug Info | [8] | |||
3 | PMID30247903-Compound-General structure15 | Drug Info | [8] |
Cell-based Target Expression Variations | Top | |||||
---|---|---|---|---|---|---|
Cell-based Target Expression Variations |
Drug Binding Sites of Target | Top | |||||
---|---|---|---|---|---|---|
Ligand Name: (2S,3R)-2-azaniumyl-3-hydroxybutanoate | Ligand Info | |||||
Structure Description | Complex structure of PD1 and 609A-Fab | PDB:7VUX | ||||
Method | X-ray diffraction | Resolution | 1.64 Å | Mutation | No | [81] |
PDB Sequence |
MWNPPTFSPA
40 LLVVTEGDNA50 TFTCSFSNTS60 ESFVLNWYRM70 SPSNQTDKLA80 AFPEDRSQPG 90 QDSRFRVTQL100 PNGRDFHMSV110 VRARRNDSGT120 YLCGAISLAP130 KAQIKESLRA 140 ELRVTERRAE150 VP
|
|||||
|
||||||
Click to View More Binding Site Information of This Target with Different Ligands |
Different Human System Profiles of Target | Top |
---|---|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Pathway Affiliation
of target is determined by the life-essential pathways provided on KEGG database. The target-affiliated pathways were defined based on the following two criteria (a) the pathways of the studied target should be life-essential for both healthy individuals and patients, and (b) the studied target should occupy an upstream position in the pathways and therefore had the ability to regulate biological function.
Targets involved in a fewer pathways have greater likelihood to be successfully developed, while those associated with more human pathways increase the chance of undesirable interferences with other human processes
(Pharmacol Rev, 58: 259-279, 2006).
Biological Network Descriptors
of target is determined based on a human protein-protein interactions (PPI) network consisting of 9,309 proteins and 52,713 PPIs, which were with a high confidence score of ≥ 0.95 collected from STRING database.
The network properties of targets based on protein-protein interactions (PPIs) have been widely adopted for the assessment of target’s druggability. Proteins with high node degree tend to have a high impact on network function through multiple interactions, while proteins with high betweenness centrality are regarded to be central for communication in interaction networks and regulate the flow of signaling information
(Front Pharmacol, 9, 1245, 2018;
Curr Opin Struct Biol. 44:134-142, 2017).
Human Similarity Proteins
Human Pathway Affiliation
Biological Network Descriptors
|
There is no similarity protein (E value < 0.005) for this target
|
KEGG Pathway | Pathway ID | Affiliated Target | Pathway Map |
---|---|---|---|
Cell adhesion molecules | hsa04514 | Affiliated Target |
|
Class: Environmental Information Processing => Signaling molecules and interaction | Pathway Hierarchy | ||
T cell receptor signaling pathway | hsa04660 | Affiliated Target |
|
Class: Organismal Systems => Immune system | Pathway Hierarchy |
Degree | 7 | Degree centrality | 7.52E-04 | Betweenness centrality | 1.51E-05 |
---|---|---|---|---|---|
Closeness centrality | 2.10E-01 | Radiality | 1.37E+01 | Clustering coefficient | 7.14E-01 |
Neighborhood connectivity | 3.14E+01 | Topological coefficient | 2.20E-01 | Eccentricity | 12 |
Download | Click to Download the Full PPI Network of This Target | ||||
Drug Property Profile of Target | Top | |
---|---|---|
(1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
||
(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
||
(5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
||
"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five |
Target Profiles in Patients | Top | |||||
---|---|---|---|---|---|---|
Target Expression Profile (TEP) |
Target Affiliated Biological Pathways | Top | |||||
---|---|---|---|---|---|---|
KEGG Pathway | [+] 2 KEGG Pathways | + | ||||
1 | Cell adhesion molecules (CAMs) | |||||
2 | T cell receptor signaling pathway | |||||
Reactome | [+] 1 Reactome Pathways | + | ||||
1 | PD-1 signaling | |||||
WikiPathways | [+] 2 WikiPathways | + | ||||
1 | T-Cell Receptor and Co-stimulatory Signaling | |||||
2 | Costimulation by the CD28 family |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. | |||||
REF 2 | 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. | |||||
REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. | |||||
REF 4 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7499). | |||||
REF 5 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7335). | |||||
REF 6 | Nivolumab, a Novel Anti D-1 Monoclonal Antibody for the Treatment of Solid and Hematologic Malignancies (Personalized Medicine in Oncology). Emma Thornton. Anti-PD-1 Therapy. June 2014 | |||||
REF 7 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||||
REF 8 | Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. | |||||
REF 9 | FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761334. | |||||
REF 10 | Sintilimab: First Global Approval. Drugs. 2019 Feb;79(3):341-346. | |||||
REF 11 | Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). Expert Opin Investig Drugs. 2020 Dec;29(12):1355-1364. | |||||
REF 12 | Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022 Jan 12;12:730666. | |||||
REF 13 | ClinicalTrials.gov (NCT00308867) Photodynamic Therapy With PD P 506 A or Its Placebo Compared With Cryosurgery for the Treatment of Mild to Moderate Actinic Keratosis. U.S.National Institutes of Health. | |||||
REF 14 | ClinicalTrials.gov (NCT04943627) A Phase 3 Trial of Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer After Platinum-Based Chemotherapy (BRAVA). U.S.National Institutes of Health. | |||||
REF 15 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 16 | ClinicalTrials.gov (NCT04194775) A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of Nofazinlimab (CS1003) in Combination With Lenvatinib Compared to Placebo in Combination With Lenvatinib as First-Line Therapy in Subjects With Advanced Hepatocellular Carcinoma (HCC). U.S.National Institutes of Health. | |||||
REF 17 | ClinicalTrials.gov (NCT02967692) A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma (COMBI-i). U.S. National Institutes of Health. | |||||
REF 18 | ClinicalTrials.gov (NCT04165317) Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (CREST). U.S. National Institutes of Health. | |||||
REF 19 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 20 | ClinicalTrials.gov (NCT04380805) A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer. U.S. National Institutes of Health. | |||||
REF 21 | ClinicalTrials.gov (NCT05216835) A Phase I/II Open-label, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma. U.S.National Institutes of Health. | |||||
REF 22 | ClinicalTrials.gov (NCT04549025) Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen (SELECT). U.S. National Institutes of Health. | |||||
REF 23 | ClinicalTrials.gov (NCT05848011) A Phase 2, Randomized, Open-Label, Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer. U.S.National Institutes of Health. | |||||
REF 24 | ClinicalTrials.gov (NCT05516758) A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Peresolimab in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis. U.S.National Institutes of Health. | |||||
REF 25 | ClinicalTrials.gov (NCT04785820) A Study of RO7121661 and RO7247669 Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus. U.S. National Institutes of Health. | |||||
REF 26 | ClinicalTrials.gov (NCT05584670) A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy in Adults With Advanced Solid Tumors. U.S.National Institutes of Health. | |||||
REF 27 | ClinicalTrials.gov (NCT05005728) Phase 2 Multiple-Dose, Multiple-Arm, Parallel Assignment Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of XmAb?20717 Alone or in Combination With Chemotherapy or Targeted Therapies in Selected Subjects With Metastatic Castration-Resistant Prostate Cancer. U.S.National Institutes of Health. | |||||
REF 28 | ClinicalTrials.gov (NCT02908906) A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers. U.S. National Institutes of Health. | |||||
REF 29 | ClinicalTrials.gov (NCT04212221) MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients. U.S. National Institutes of Health. | |||||
REF 30 | ClinicalTrials.gov (NCT04995523) Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC. U.S.National Institutes of Health. | |||||
REF 31 | ClinicalTrials.gov (NCT03950297) Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A. U.S. National Institutes of Health. | |||||
REF 32 | Clinical pipeline report, company report or official report of Novartis. | |||||
REF 33 | ClinicalTrials.gov (NCT03853109) AMG 404 in Patients With Advanced Solid Tumors.. U.S. National Institutes of Health. | |||||
REF 34 | ClinicalTrials.gov (NCT01352884) Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer. U.S. National Institutes of Health. | |||||
REF 35 | ClinicalTrials.gov (NCT03053466) APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors. U.S. National Institutes of Health. | |||||
REF 36 | ClinicalTrials.gov (NCT02952248) A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours. U.S. National Institutes of Health. | |||||
REF 37 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 38 | ClinicalTrials.gov (NCT04440943) A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies. U.S. National Institutes of Health. | |||||
REF 39 | ClinicalTrials.gov (NCT04777084) The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC.. U.S. National Institutes of Health. | |||||
REF 40 | A Phase Ib/II open-label study to evaluate the safety and efficacy of MEDI-551 in combination with immunomodulating therapy in patients with relapsed or refractory aggressive B cell lymphomas. J Immunother Cancer. 2014; 2(Suppl 3): P73. | |||||
REF 41 | ClinicalTrials.gov (NCT03530397) A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health. | |||||
REF 42 | ClinicalTrials.gov (NCT03761017) MGD019 DART Protein in Unresectable/Metastatic Cancer. U.S. National Institutes of Health. | |||||
REF 43 | ClinicalTrials.gov (NCT04140500) Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors. U.S. National Institutes of Health. | |||||
REF 44 | ClinicalTrials.gov (NCT04303858) A Study to Evaluate Safety and Anti-Tumor Activity of RO7284755 Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors. U.S. National Institutes of Health. | |||||
REF 45 | ClinicalTrials.gov (NCT04606472) A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors. U.S. National Institutes of Health. | |||||
REF 46 | ClinicalTrials.gov (NCT04363242) A Study to Find the Maximum Tolerated Dose (MTD) of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People With Cancer of the Internal or External Lining of the Body.. U.S. National Institutes of Health. | |||||
REF 47 | ClinicalTrials.gov (NCT03752398) A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3). U.S. National Institutes of Health. | |||||
REF 48 | A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. | |||||
REF 49 | Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Future Oncol. 2021 Mar;17(8):877-892. | |||||
REF 50 | Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022 Jan 12;12:730666. | |||||
REF 51 | A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study). Lung Cancer. 2023 Oct;184:107355. | |||||
REF 52 | Clinical pipeline report, company report or official report of Agenus Lexington | |||||
REF 53 | CS1003, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer therapy. Acta Pharmacol Sin. 2021 Jan;42(1):142-148. | |||||
REF 54 | Clinical pipeline report, company report or official report of EQRx | |||||
REF 55 | Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody. Mol Cancer Ther. 2020 Oct;19(10):2105-2116. | |||||
REF 56 | Clinical pipeline report, company report or official report of Akeso Biopharma. | |||||
REF 57 | Clinical pipeline report, company report or official report of AstraZeneca | |||||
REF 58 | Clinical pipeline report, company report or official report of Jounce Therapeutics. | |||||
REF 59 | Clinical pipeline report, company report or official report of MacroGenics | |||||
REF 60 | A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis. N Engl J Med. 2023 May 18;388(20):1853-1862. | |||||
REF 61 | Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608. | |||||
REF 62 | Clinical pipeline report, company report or official report of Sanofi | |||||
REF 63 | Clinical pipeline report, company report or official report of Xencor | |||||
REF 64 | Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update. Int J Mol Sci. 2018 Dec 7;19(12):3924. | |||||
REF 65 | Clinical pipeline report, company report or official report of 3SBio. | |||||
REF 66 | National Cancer Institute Drug Dictionary (drug id 700595). | |||||
REF 67 | Clinical pipeline report, company report or official report of Apollomics. | |||||
REF 68 | Clinical pipeline report, company report or official report of Boehringer Ingelheim. | |||||
REF 69 | Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy. Cancer Immunol Immunother. 2020 Oct;69(10):2125-2137. | |||||
REF 70 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2760). | |||||
REF 71 | Clinical pipeline report, company report or official report of Innovent. | |||||
REF 72 | Bispecific Antibodies to PD-1 and CTLA4: Doubling Down on T Cells to Decouple Efficacy from Toxicity. Cancer Discov. 2021 May;11(5):1008-1010. | |||||
REF 73 | Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule. Cell Rep Med. 2020 Dec 22;1(9):100163. | |||||
REF 74 | Clinical pipeline report, company report or official report of Genentech. | |||||
REF 75 | Clinical pipeline report, company report or official report of Roche. | |||||
REF 76 | Clinical pipeline report, company report or official report of SystImmune. | |||||
REF 77 | Clinical pipeline report, company report or official report of Symphogen. | |||||
REF 78 | Clinical pipeline report, company report or official report of Xencor. | |||||
REF 79 | Clinical pipeline report, company report or official report of Xencor. | |||||
REF 80 | Clinical pipeline report, company report or official report of Biocytogen | |||||
REF 81 | A strategy for the efficient construction of anti-PD1-based bispecific antibodies with desired IgG-like properties. MAbs. 2022 Jan-Dec;14(1):2044435. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.